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individuals who indicate they have no chronic health condition. Results are compared 
using mean errors (ME), root mean squared errors (RMSE) and the proportion of 
values estimated within |0.05|. RESULTS: Using an age adjusted baseline, we found 
the additive (and multiplicative) methods underestimate the majority of HSUVs 
(ME:0.0781(0.0254); RMSE:0.1012(0.0651); 26%(56%) < |0.05|) while the minimum 
(and ADE) overestimate the majority of HSUVs (ME:−0.0995(−0.0695); 
RMSE:0.1214(0.0950); 20%(35%) < |0.05|). Although the simple linear model pro-
duced the most accurate results (ME:0.0001; RMSE:0.0598; 63% < |0.05|), there were 
some substantial errors with 20% of errors greater than the minimum important 
difference (|0.074|). When subgrouping by actual HSUV (range 0.350–0.917) we 
found the magnitude and direction of errors in the estimated HSUVs are driven by 
the actual HSUVs being estimated in addition to the technique used. In general the 
HSUVs estimated using an adjusted baseline were more accurate than those obtained 
using a baseline of perfect health. CONCLUSIONS: This study makes an important 
contribution to the evidence in this area as it is the ﬁ rst to compare the ﬁ ve different 
techniques in the same data set. While the simple linear model gave the most accurate 
results, the model requires validating in external data and additional research explor-
ing an alternative model speciﬁ cation is warranted.
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OBJECTIVES: Caregiver rating scales, intended to evaluate the behaviour of children 
and young people, are frequently used in clinical trials involving youths. However, the 
translation and linguistic validation of such scales can be problematic due to the differing 
cultural markers of behaviour and development. This study aims to document the 
problems that can occur, with the hope of facilitating future studies and producing 
guidelines to avoid cultural compromises when such measures are developed. 
METHODS: Past Oxford Outcomes projects, which included the translation of Care-
giver Reported Outcomes, were evaluated to identify problematic items. These included 
the Vineland-II and ABAS (behaviour development scales), ELDQOL (epilepsy and QoL 
scale) and WFI-RS (functional impairment rating scale) among others. RESULTS: 
Numerous cultural and linguistic issues became apparent, including the following:—
Many examples of sports and activities were used in the documents, which required 
thorough cultural adaptation, e.g. types of games.—Logistical cultural differences were 
marked, e.g. questionnaires mentioned children’s understanding of speciﬁ c coins or 
trafﬁ c signals, which vary culturally.—Some documents involved markers for identifying 
speech development, such correct use of irregular verbs. These were problematic in other 
cultures and speech development specialists were required to ﬁ nd suitable alternatives.—
More idiomatic expressions are used than in PROs developed for adults, e.g. “on the 
go”; these cause difﬁ culties in translation.—Items surrounding activities such as house-
work or helping look after siblings are not equivalent in some cultures due to differing 
role expectations. CONCLUSIONS: The validation of caregiver reported outcomes 
through interviews with caregivers was particularly important with these scales to ensure 
cultural appropriateness in target languages. Physician or specialist input was sometimes 
required to ﬁ nd culturally relevant alternatives. When such measures are created, cultur-
ally speciﬁ c markers of behaviour should be avoided if possible.
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OBJECTIVES: Almost four years were necessary to develop the ﬁ nal FDA guidance 
on the use of PRO measures in clinical trials. Our objective is to compare how the 
recommendations about translation and cultural adaptation evolved from the 2006 
draft to the 2009 ﬁ nal guidance. METHODS: Both guidances were retrieved on the 
FDA website and analyzed. RESULTS: Structure and content were modiﬁ ed. Recom-
mendations on translation and cultural adaptation were moved to another section 
within the Evaluating PRO Instruments Part: from “IV.D. Modiﬁ cation of an existing 
instrument” to “III.G. PRO Instruments intended for speciﬁ c populations”. As for 
the content, the text in the body of the ﬁ nal guidance is more concise compared to 
the draft. The novelty lies in the stipulation that the FDA will review the process used 
to translate/culturally adapt the instruments. As a consequence, an appendix (section 
VIII) was added in which the FDA explains which topics should be addressed in the 
documents provided to the FDA for review: description of process used, patient 
testing, rationale for decisions, copies of versions and evidence about validity. They 
are however key points which did not change: the need for providing evidence that 
content validity and other measurement properties are similar between all versions. 
CONCLUSIONS: The recommendations are more concise and precise, especially the 
expectations of the FDA. The FDA however does not indicate a preference for a 
speciﬁ c translation methodology. Interestingly patient testing is clearly indicated as a 
key point of the process. The need for documenting all decisions is crucial and raises 
the question of developing standardized system of reporting to structure the evidence 
to be provided to the FDA. The last point of the Appendix is debatable as we anticipate 
that it might add a burden in term of costs to provide evidence about the psychometrics 
of all versions.
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OBJECTIVES: To determine how often SF-36 Health Survey measures respond to 
efﬁ cacious pharmaceutical treatment beneﬁ ts in well-controlled clinical trials. 
METHODS: We conducted a systematic review of randomized, double-blind, placebo-
controlled trials published in 124 journals in 1995 through 2009 documenting differ-
ences between treatment groups for primary medical endpoints and any of the SF-36 
component summaries, or eight subscale scores. Concordance was deﬁ ned in terms of 
agreement between primary clinical and SF-36 endpoints (both statistically signiﬁ cant 
or both non-signiﬁ cant). RESULTS: A review of 2,020 identiﬁ ed clinical trials using 
the SF-36 conﬁ rmed that 162 met study design criteria. For 133 of 162 trials (82.1%), 
results for primary clinical endpoints and SF-36 measures were concordant. Among 
the 107 trials achieving medical efﬁ cacy (primary endpoint), changes in one or more 
SF-36 measures were also signiﬁ cant, as hypothesized, for 88 (82.2%). Similar patterns 
were observed by therapeutic area; for example: rheumatology (29 of 30), neurology 
(16 of 25), cardiovascular (15 of 18), pulmonary (11 of 13), psychiatry (8 of 10), 
endocrine (7 of 9), and combined surgical specialties (9 of 9) studies demonstrated 
concordance. In addition to evaluating characteristics of published reports and scoring 
methods (subscales, summaries, utility scoring) this presentation will comment on 
priorities for future studies of patient-reported outcomes (PROs) in evaluations of 
pharmaceutical and other medical treatments. CONCLUSIONS: In support of their 
validity as PROs, changes in SF-36 measurements agree with primary endpoints in 
over 8 out of 10 well-controlled trials of pharmaceutical therapies published to date. 
In support of pharmaceuticals’ efﬁ cacy, when a therapy positively impacted clinical 
endpoints, it also improved health related quality of life quality of life in over 8 out 
of 10 clinical trials published to date.
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OBJECTIVES: Although the ability to interact with patients in an on-line environment 
has expanded substantially over the past few years, many researchers are concerned 
that participants may not be representative from a medication experience perspective 
(i.e., biased towards complainers). The purpose of this study is to investigate patient 
responses on treatment satisfaction using a validated PRO measure, the Treatment 
Satisfaction Questionnaire for Medications (TSQM), collected through a survey of 
patients with depression from an on-line community. METHODS: A random sample 
of iGuard.org members treated with an antidepressant were invited to complete an 
online version of the TSQM, a widely used validated 14-item generic treatment satis-
faction instrument. iGuard.org is an online patient community that provides a free 
medication monitoring service to patients. Non-parametric item response analyses 
were performed to determine the relationship between scores on individual items and 
total TSQM scores. RESULTS: Responses from 3641 patients were included in the 
analyses. TSQM Global Satisfaction scores ranged from 0—100 suggesting a broad 
spectrum of treatment satisfaction. Non-parametric Item Response analyses of raw 
scores revealed that individual items of the TSQM discriminated differences in patient 
satisfaction. That is, as total scores increased the probability of low scores on the 
individual items decreased and the probability of higher scores increased. As expected, 
patient satisfaction was related to reported side-effects, with those reporting side-
effects experiencing lower satisfaction with medication than those without reported 
side-effects. CONCLUSIONS: The results from this analysis suggest that PRO survey 
data collected through a random sample of members of the on-line patient community 
iGuard.org can be representative of the spectrum of anticipated treatment satisfaction 
responses. Continuing to explore the potential of direct data capture from on-line 
patients will be important as researchers seek faster and cheaper alternatives to tradi-
tional physician-based recruitment.
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BACKGROUND: Most outcomes instruments have been developed and validated as 
paper versions, but few have been migrated to electronic format. Migration to elec-
tronic delivery, without signiﬁ cantly altering format or text, qualiﬁ es as a minor 
modiﬁ cation not requiring a full validation (Coons et al. 2009). However, this does 
not mean that the two formats are perceived in the same way by patients. We aim 
here to describe a methodology successfully used to establish equivalence between 
paper and electronic PROs. METHODS: To demonstrate the equality of these differ-
ent modes of data collection, we have used a combination of “think-aloud” and ret-
rospective cognitive debrieﬁ ng techniques, as well as usability testing. The debrieﬁ ng 
exercise is designed to assess whether the electronic device changes the way respon-
dents interpret the questions or response options. The usability testing assesses 
ease of use and identiﬁ es issues that may prohibit the use of the ePRO by the target 
